872715-62-3

Basic information

• Product Name: 1-Boc-3-aminomethyl-4-hydroxypyrrolidine
• Synonyms: 1-Boc-3-aminomethyl-4-hydroxypyrrolidine;tert-butyl trans-3-(aminomethyl)-4-hydroxypyrrolidine-1-carboxylate;TRANS-1-BOC-3-HYDROXY-4-AMINOMETHYLPYRROLIDINE;1-Pyrrolidinecarboxylic acid, 3-(aminomethyl)-4-hydroxy-,1,1-dimethylethyl ester, (3R,4S)-rel-
• CAS NO: 872715-62-3
• Molecular Formula: C10H20N2O3
• Molecular Weight: 216.28
• Mol File: 872715-62-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-3-aminomethyl-4-hydroxypyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-3-aminomethyl-4-hydroxypyrrolidine(872715-62-3)
• EPA Substance Registry System: 1-Boc-3-aminomethyl-4-hydroxypyrrolidine(872715-62-3)

Safety Data

• Hazardous Substances Data: 872715-62-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Boc-3-aminomethyl-4-hydroxypyrrolidine is used as a key building block in the synthesis of pharmaceuticals, particularly for the development of enantiomerically pure compounds. Its ability to introduce a chiral center into molecules is crucial for creating drugs with specific biological activities and minimizing potential side effects.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-Boc-3-aminomethyl-4-hydroxypyrrolidine is used as a precursor for the design and synthesis of novel therapeutic agents. Its potential as an anti-cancer agent is currently being investigated, with research focusing on its ability to target and inhibit the growth of cancer cells.
Used in Neurological Disorder Treatment:
1-Boc-3-aminomethyl-4-hydroxypyrrolidine is also being explored for its potential role in the treatment of neurological disorders. Its unique structural features and reactivity may contribute to the development of new drugs aimed at addressing various neurological conditions.
Used in Organic Chemistry:
In the realm of organic chemistry, 1-Boc-3-aminomethyl-4-hydroxypyrrolidine serves as an important intermediate for the synthesis of a wide range of organic compounds. Its versatility and the presence of the Boc protecting group make it a valuable tool for chemists in the development of new synthetic routes and methodologies.

Upstream product

• 197143-33-2 tert-butyl 3-cyano-4-hydroxypyrrolidine-1-carboxylate 
• 44981-94-4 N-cyanoethyl glycine ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 175463-32-8 3-cyano-4-oxopyrrolidine-1-carboxylic acid tert-butyl ester 
• 266353-18-8 N-tert-butoxycarbonyl-2-(2-cyanoethyl)aminoacetic acid ethyl ester 
• 872714-81-3 tert-butyl (3S,4S)-3-((((benzyloxy)carbonyl)amino)methyl)-4-hydroxypyrrolidine-1-carboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 

Downstream Products

• 872716-50-2 1,1-dimethylethyl 3-hydroxy-4-[({[(phenylmethyl)oxy]carbonyl}amino)methyl]-1-pyrrolidinecarboxylate 

Relevant articles and documents

Preparation and application of imidazo aromatic ring compounds

The invention provides preparation and application of imidazo aromatic ring compounds, and particularly provides compounds as shown in the following formula I. The definition of each group is as shownin the specification. The compounds have TRK kinase inh

FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS

Bicyclic nitrogen containing compounds of formula (I) and their use as antibacterials.

NOVEL COMPOUNDS

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted pyrrolidines, according to Formula (I) specifically, the invention is di

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Synthesis and biological activity of novel 1β-Methylcarbapenems with oxyiminopyrrolidinylamide moiety

The synthesis and antibacterial activity of novel 1β- methylcarbapenems 1a-f bearing oxyiminopyrrolidinylamide moiety at C-5 position of pyrrolidine are described. Most compounds exhibited comparable antibacterial activity to meropenem against a wide range of Gram-positive and Gram-negative organisms including Pseudomonas aeruginosa isolates. Of these carbapenems, 1a showed potent and broad spectrum of antibacterial activity and similar stability to DHP-I to meropenem. Against clinical isolates of 40 Gram-negative bacterial species including MDR and ESBL-producing strains, the selected carbapenem 1a possessed excellent in vitro activity except for MDR P. aeruginosa, and was comparable in potency to meropenem.

Discovery of gemifloxacin (Factive, LB20304a): A quinolone of new a generation

Novel quinolone antibacterials, which bear an alkyloxime substituent in the 4-position and an aminomethyl substituent in the 3-position of the pyrrolidine ring, have been designed and synthesized. These fluoroquinolones were found to possess extremely potent antimicrobial activity against Gram-positive organisms including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA). Among these compounds our development candidate, Gemifloxacin (Factive, LB20304a), showed the best in vivo efficacy and pharmacokinetic profile in animals, as well as good safety pharmacological properties. Gemifloxacin was found to be especially effective against respiratory tract infections that account for over 70% of all infections. With once-a-day dosage, potency against respiratory tract infections such as chronic bronchitis and pneumonia was ensured without any significant side effect. In December 1999, Gemifloxacin filed a NDA for marketing approval to the US Food and Drug Administration. Copyright

Novel fluoroquinolone antibacterial agents containing oxime-substituted (Aminomethyl)pyrrolidines: Synthesis and antibacterial activity of 7-(4- (Aminomethyl)-3-(methoxyimino) pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4- oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304)

New pyrrolidine derivatives, which bear an alkyloxime substituent in the 4-position and an aminomethyl substituent in the 3-position of the pyrrolidine ring, have been synthesized and coupled with various quinolinecarboxylic acids to produce a series of new fluoroquinolone antibacterials. These fluoroquinolones were found to possess potent antimicrobial activity against both Gram-negative and Gram-positive organisms, including methicillin resistant Staphylococcus aureus (MRSA). Variations at the C-8 position of the quinolone nucleus included fluorine, chlorine, nitrogen, methoxy, and hydrogen atom substitution. The activity imparted to the substituted quinolone nucleus by the C-8 substituent was in the order F (C5-NH2) > F (C5-H) > naphthyridine > Cl = OMe = H against Gram-positive organisms. In the case of Gram-negative strains, activity was in the order F (C5-NH2) > naphthyridine = F (C5-H) > H > Cl > OMe. The advantages provided by the newly introduced oxime group of the quinolones were clearly demonstrated by their comparison to a desoximino compound 30. In addition, the oxime moiety greatly improved the pharmacokinetic parameters of the novel quinolones. Among these compounds, compound 20 (LB20304) showed the best in vive efficacy and pharmacokinetic profile in animals, as well as good physical properties. The MICs (μg/mL) of LB20304, compound 30, and ciprofloxacin against several test organisms are as follows: S. aureus 6538p (0.008, 0.031, and 0.13), methicillin resistant S. aureus 241 (4, 16, and 128), Streptococcus epidermidis 887E (0.008, 0.016, and 0.13), methicillin resistant S. epidermidis 178 (4, 32, and 128), Enterococcus faecalis 29212 (0.063, 0.13, and 1), Pseudomonas aeruginosa 1912E (0.25, 0.5, and 0.13), Escherichia coli 3190Y (0.008, 0.016, and 0.008), Enterobacter cloacae P99 (0.008, 0.031, and 0.008), Actinobacter calcoaceticus 15473 (0.063, 0.13, and 0.25). On the basis of these promising results, LB20304 was selected as a candidate for further evaluation.